|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Exelixis Inc: Premium Company Profile |
|
|
|
|
€ 396,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2007 |
Taille du document : |
58 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 162 pages | Septembre 2006 | Anglais
|
|
|
| Main
focus: |
cancer
|
| Research
focus: |
market definition,market outlook, |
| Geographic
focus: |
france,canada,finland,switzerland,norway,sweden,... |
| |
|
|
|
|
| 162 pages | Octobre 2006 | Anglais
|
|
|
| Main
focus: |
cancer
|
| Research
focus: |
market definition,market outlook, |
| Geographic
focus: |
france,canada,switzerland,finland,mauritius,usa,... |
| |
|
|
|
|
| 92 pages | Février 2008 | Anglais
|
|
|
| Main
focus: |
cancer,oncology,lymphoma,breast cancer,...,...
|
| Research
focus: |
market size and estimates,market definition, |
| Geographic
focus: |
usa,france,germany,united kingdom,switzerland,... |
| |
|
|
|
|
| 456 pages | Mai 1999 | Anglais
|
|
|
| Main
focus: |
cancer,breast cancer,lung cancer,health care,...
|
| Research
focus: |
market outlook,market definition,demand analysis, |
| Geographic
focus: |
usa,india |
| |
|
|
|
|
| 74 pages | Janvier 2002 | Anglais
|
|
|
| Main
focus: |
cancer,breast cancer,prostate cancer,lung cancer,...,...
|
| Research
focus: |
market definition,market outlook |
| Geographic
focus: |
canada,france,australia |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmaceutical Packaging Market 80 pages | Avril 2002 |
This report will enable you to:Analyse the size of the UK market for pharmaceutical packaging between 1997 and 2006, by type: - cartons - containers - labels and leaflets - blister & strip p |
1 479,00 €
|
| |
| |
OTC Cough and Cold Remedies in Germany 15 pages | Juillet 2002 |
The German market for OTC cough and cold remedies reached a value of Euro 972 million (US$ 918 million) in 2001, up 0.4% on the previous year. During the review period, the market grew by 9.4%, an |
198,00 €
|
| |
| |
The Pharmaceutical Distribution Outlook 1998-2008 165 pages | Octobre 1998 |
Industry growth and consolidation means that pharmaceutical manufacturers are no longer geographically limited in their operations and now market their products globally, creating a vast commercia |
795,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium 240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years. Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Healthcare In Scotland 52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
The Pharmaceutical Profitability Outlook 150 pages | Février 1999 |
Is pharmaceutical profitability sustainable into the 21st century? “As the pharmaceutical industry finds itself at a crossroads, the strategic directions companies take will be pivotal in determini |
795,00 €
|
| |
| |
The Generics Outlook 2001 242 pages | Février 2001 |
By the year 2004, it is expected that the value of the total western European generics sector may have risen to $19 billion, representing almost 15% of allpharmaceuticals. In the USA, the val |
955,00 €
|
| |
| |
The Pharmaceutical Mergers and Acquisitions Outlook 2001 128 pages | Octobre 2001 |
Pharmaceutical companies have recently undertaken extensive M&A activity to either build critical mass, create organic growth or through strategic alliances to build virtual mass. The Pharmaceu |
1 200,00 €
|
| |
| |
Healthcare In Wales 50 pages | Mai 2000 |
The Welsh Presentation Includes:- The Structure Of The NHS In Wales- Revenue Expenditure On Health Services In Wales- Number Of Hospital Units - Number Of Available Inpatient Beds- Number Of Occupied |
327,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Exelixis Inc: Premium Company Profile |
|
|
Introduction
Exelixis is a development-stage biotechnology company dedicated to the discovery and development of small molecule therapeutics for the treatment of cancer and other serious diseases. The company has a fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer.
Scope
Contains corporate strategy, value chain presence and SWOT AnalysisProvides detailed business description, segment analysis, 5-year financial trends, key products and key competitorsIncludes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Exelixis is experienced in discovering and developing therapeutics for cancer and renal diseases. The company has in-house and collaborative pipeline products and currently has no marketed products.
The company derives its revenues from contract, licensing and collaboration. During 2002-2006, the company's total revenues grew at a CAGR of 22% from $44 million in 2002 to $99 million in 2006.
During the period 2006-2010, licensing, collaboration and other revenues are forecasted to grow from $99 million to $301 million. Licensing, collaboration and others would remain to be the sole revenue contributor as the company does not have any launch product or expect to launch over the period 2006-2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single reportUnderstand company's strengths, weaknesses, opportunities and threats along with business strategy and value chainGain access to company's adjusted five year financial data along with key ratios and market capitalization
|
|
TABLE OF CONTENTS Overview 1 Catalyst 1 Summary 1 Company Structure 6 Company Overview and Key Facts 6 Business Description 7 History 10 Locations and Subsidiaries 15 Company Financials 16 Stock Market Performance 16 P&L 18 Balance Sheet 21 Cash Flow 21 Business Segment Performance 22 Products & Services 23 Pipeline Products 23 AC Forecast Product Sales 28 Competitors and Strategic Business Relationships 29 Key Competitors 29 Key Suppliers 29 Key Clients 29 Shareholding Structure 30 Strategy 31 Company View 31 Corporate Strategy 34 SWOT Analysis 37 Overview 37 Strengths 38 Weaknesses 40 Opportunities 41 Threats 42 Value Chain Analysis 43 Discovery and Product Development 43 Scorecard 45 Overview 45 Scorecard Analysis 46 Key Employees 47 Key Employee Biographies 48 Financial and Operational Overview 56 Financial and Operational Overview 56 APPENDIX 58 Ask the analyst 58 Datamonitor consulting 58 Disclaimer 58
TABLE OF FIGURES Figure 1: Exelixis - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 19
TABLE OF TABLES Table 1: Exelixis - Key Facts 6 Table 2: Exelixis - Locations and Subsidiaries 15 Table 3: Exelixis - Year-End Share Price and Market Capitalization, 2002-2006 ($) 16 Table 4: Exelixis - Key Events Impacting Share Price Performance 17 Table 5: Exelixis - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 18 Table 6: Exelixis - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 20 Table 7: Exelixis - Balance Sheet, 2002-2006 ($ Mn) 21 Table 8: Exelixis - Cash Flow, 2002-2006 ($ Mn) 21 Table 9: Exelixis - Revenue Breakdown by Division, 2002-2006 ($ Mn) 22 Table 10: Exelixis - In-house Pipeline Products 23 Table 11: Exelixis - Collaboration Products 25 Table 12: Exelixis - Forecast Sales, 2006-2010 ($ Mn) 28 Table 13: Exelixis - Key Competitors 29 Table 14: Exelixis - Key Clients 29 Table 15: Exelixis - Key Shareholders 30 Table 16: Exelixis - SWOT Analysis Summary 37 Table 17: Exelixis - Value Chain Analysis 43 Table 18: Exelixis - Scorecard 45 Table 19: Exelixis - Key Employees 47 Table 20: Exelixis - Financial and Operational Overview 56
|
|
|
PPLSEN
|
|
|
|
|